

VOICE OF YORUBA



NEWSLETTER OF **Egbé Ọmọ Yorùbá**
OF GREATER MIAMI VALLEY

www.VoiceOfYoruba.org

VOY is published quarterly in March, June, September, and December

March 2022
Vol. 13, No. 1


Designed to Inform and Entertain

<u>Major Contents</u>	Page
President’s Message.....	2
Women’s Health.....	3
Dignity of Womanhood.....	10
Shipment Service to Nigeria.....	11

This is the March issue of VOY.

**March is Women’s History Month
In VOY Parlance, this is also the month of
demonstrating Black Women’s power, influence, and
resourcefulness.**

The message of Egbe’s president, which appears on the following page, aptly demonstrates the above reality.



From The President's Corner



With glory to God Almighty, our Egbe's monthly Zoom meetings continue to be well-attended. Our meetings are always highly refreshing and focused on Egbe's vision and mission. The opportunity to re-connect and perform Egbe's obligations in a very light, jovial mode of adages and jokes ("fabu") sharing, is one that everyone anxiously looks forward to as no one leaves the meeting without getting a full dose of deep-hearted laughter. In order to further increase the fun we have virtually, the Zoom typically starts fifteen (15) to thirty (30) minutes before time with delightful music courtesy of our one and only Disc Jockey, Prof. Deji Badiru, who is yet to disappoint us with his awesome music selections from various Nigerian artists. In the same way, members enjoy more delightful music that we dance to as we exchange pleasantries after the meeting is adjourned –

sometimes lasting another twenty (15) to thirty (30) minutes. Needless to say that it is typically fun, fun, and more fun time.

The first quarter of year 2022 brought four (4) exceptional new members to our midst: (1) Mrs. Tola Tope Anderson, a well-known, seasoned culinary expert in the US; (2) Mr. Joshua Adesina, a Wright State University Graduate student in Engineering; (3) Dr. Abayomi Ogunderu, a highly recognized medical doctor with exceptional fluency in Yoruba language; and (4) Mr. Habib Ajose, a Wright State University Graduate student in Engineering.

As we approach the second quarter of 2022, it is my hope that the Egbe will be blessed with additional new members and that the prevalence of Corona Virus will get to a level that allows in-person meetings where our traditional home-made, mouth-watering cuisine is, once again, gladly enjoyed together.

Dr. (Mrs.) Funmi Adegbile, President

Women's Health Upfront

In previous issues of Voice of Yoruba (VOY), we presented guides and hints on Men's Health, particularly about Prostate Cancer. In this issue, we put women's health upfront by presenting a timely article on **Ovarian Cancer**, which is listed as one of the leading causes of cancer deaths for women. Experts categorize ovarian cancer as one of the deadliest gynecologic malignancies. This is of particular interest because we know of friends, family, and/or colleagues who have succumbed to ovarian cancer in recent times.

To preserve and promote the message, the article below is presented verbatim, as published in the **Women's Health magazine**, a supplement to **USA Today** newspaper, which the VOY editor had the good chance of reading on a recent flight to Dallas, Texas. Enjoy the reading.

Source: <https://www.futureofpersonalhealth.com/womens-health/a-novel-treatment-for-ovarian-cancer-needs-patients-for-clinical-trial/>

A Novel Treatment for Ovarian Cancer Needs Patients for Clinical Trial

The Celsion Corporation is developing a novel treatment for ovarian cancer that, in tandem with chemotherapy, is prolonging the lives of patients.

The Celsion Corporation is dedicated to researching new treatments for cancer. One of their current clinical trials involves a novel therapy for ovarian cancer called GEN-1, which is showing signs of improving patients' chances of eliminating cancer cells during chemotherapy.

Dr. Premal Thaker

Professor in Gynecologic Oncology, Washington University School of Medicine

"In the United States, approximately 20,000 cases of ovarian cancer will be diagnosed each year," says Dr. Premal Thaker, professor in gynecologic oncology at Washington University

School of Medicine, who is helping lead Celsion's clinical trial. "It will kill approximately 13,000 of those women, making ovarian cancer one of the deadliest gynecologic malignancies."

Ovarian cancer is often difficult to cure because it's typically detected and diagnosed when it's already progressed to a late stage. "Symptoms for ovarian cancer are very vague," Thaker says. "They could be simple, like changes in bowel habits, changes in urination, or changes in appetite." However, these symptoms are often thought of as just a normal part of aging. "Because it's not detected early, these patients often present with metastatic disease. That's why they unfortunately don't have as many curative treatment options. The cancer is already well established by the time they come to diagnosis."

A potential new treatment option

Treatments for ovarian cancer are currently limited to surgery and chemotherapy. "Ideally we try to have patients undergo surgery if they're thought to be medically fit," says Thaker. Doctors will check to make sure they're able to remove all the cancer surgically, which can be difficult. The second treatment option is chemotherapy followed by surgery.

Celsion's innovation with GEN-1 is to inject an immunotherapy agent — an IL-12 DNA plasmid vector — directly to the site of the cancer, which, along with intravenous chemotherapy, directly targets the cancer cells and helps boost the body's immune system. "It's novel because we're able to actually get the medication to patients in the abdominal cavity where the cancer is," Thaker explains. "When we give chemotherapy first, the idea is to shrink the tumor so that surgery can be more successful in removing the entire tumor. We are studying to see whether GEN-1 improves this paradigm of therapy."

GEN-1 is administered every week to patients in the clinical trial, concurrently with their chemotherapy treatments every three weeks. "We can see these changes in the cancer cells biologically, which is very encouraging for us because chemotherapy is definitely helpful, but it obviously is not enough to keep the cancer away," says Thaker.

Hope TC being examined by Dr. Premal Thaker at Washington University School of Medicine/Siteman Cancer Center, Photo Courtesy of Department of Gynecologic Oncology, Washington University School of Medicine


The importance of trial participation

GEN-1 is currently in a randomized Phase 2 clinical trial called OVATION 2, with spaces still open to patients wanting to participate. However, the COVID-19 pandemic has made it harder for medical centers to enlist patients into these vital clinical trials. "COVID-19 has definitely not helped with encouraging patients to enroll in clinical trials, mainly because patients are scared to come to medical centers," Thaker explains. "My concern is that some of those patients who are really fearful may never get to us."

Thaker reminds patients and those suffering with ovarian cancer that participating in clinical trials is the best hope for better treatments to be discovered. “Remember that the treatments we accept today as standard of care are because of brave people ahead of you who participated in clinical trials,” she says.

Cancer treatments have been a challenging area of research for decades. What gives Thaker hope is seeing these advances such as GEN-1 which are giving patients a better chance at winning the fight with cancer. “The real bottom line for me is that we want to have hope for these women so that we can have better outcomes,” she says. “I feel like breast cancer gets a lot of attention and a lot of great press. However, ovarian cancer equally deserves that attention because these women are fighters and want to be part of that survivorship.” To learn more about the OVATION 2 study, please visit www.ovariancancerstudy.com.

Author: Ross Elliott, us.editorial@mediaplanet.com
March 30, 2022



A Novel Treatment for Ovarian Cancer Needs Patients for Clinical Trial

The Celsion Corporation is developing a novel treatment for ovarian cancer that, in tandem with chemotherapy, is prolonging the lives of patients.

The Celsion Corporation is dedicated to researching new treatments for cancer. One of their current clinical trials involves a novel therapy for ovarian cancer called GEN-1, which is showing signs of improving patients' chances of eliminating cancer cells during chemotherapy.

"In the United States, approximately 20,000 cases of ovarian cancer will be diagnosed each year," says Dr. Premal Thaker, professor in gynecologic oncology at Washington University School of Medicine, who is helping lead Celsion's clinical trial. "It will kill approximately 13,000 of those women, making ovarian cancer one of the deadliest gynecologic malignancies."

Ovarian cancer is often difficult to cure because it's typically detected and diagnosed when it's already progressed to a late stage. "Symptoms for

ovarian cancer are very vague," Thaker says. "They could be simple, like changes in bowel habits, changes in urination, or changes in appetite." However, these symptoms are often thought of as just a normal part of aging. "Because it's not detected early, these patients often present with metastatic disease. That's why they unfortunately don't have as many curative treatment options. The cancer is already well established by the time they come to diagnosis."

A potential new treatment option

Treatments for ovarian cancer are currently limited to surgery and chemotherapy. "Ideally we try to have patients undergo surgery if they're thought to be medically fit," says Thaker. Doctors will check to make sure they're able to remove all the cancer surgically, which can be difficult. The second treatment option is chemo-

therapy followed by surgery.

Celsion's innovation with GEN-1 is to inject an immunotherapy agent — an IL-12 DNA plasmid vector — directly to the site of the cancer, which, along with intravenous chemotherapy, directly targets the cancer cells and helps boost the body's immune system. "It's novel because we're able to actually get the medication to patients in the abdominal cavity where the cancer is," Thaker explains. "When we give chemotherapy first, the idea is to shrink the tumor so that surgery can be more successful in removing the entire tumor. We are studying to see whether GEN-1 improves this paradigm of therapy."

GEN-1 is administered every week to patients in the clinical trial, concurrently with their chemotherapy treatments every three weeks. "We can see these changes in the cancer cells biologically, which is very encouraging for us because

chemotherapy is definitely helpful, but it obviously is not enough to keep the cancer away," says Thaker.

The importance of trial participation

GEN-1 is currently in a randomized Phase 2 clinical trial called OVATION 2, with spaces still open to patients wanting to participate. However, the COVID-19 pandemic has made it harder for medical centers to enlist patients into these vital clinical trials. "COVID has definitely not helped with encouraging patients to enroll in clinical trials, mainly because patients are scared to come to medical centers," Thaker explains. "My concern is that some of those patients who are really fearful may never get to us."

Thaker reminds patients and those suffering with ovarian cancer that participating in clinical trials is the best hope for better treatments to

be discovered. "Remember that the treatments we accept today as standard of care are because of brave people ahead of you who participated in clinical trials," she says.

Cancer treatments have been a challenging area of research for decades. What gives Thaker hope is seeing these advances such as GEN-1 which are giving patients a better chance at winning the fight with cancer. "The real bottom line for me is that we want to have hope for these women so that we can have better outcomes," she says. "I feel like breast cancer gets a lot of attention and a lot of great press. However, ovarian cancer equally deserves that attention because these women are fighters and want to be part of that survivorship." To learn more about the OVATION 2 study, please visit www.ovariancancerstudy.com □

Ross Elliott

@MEDIAPLANETUSA @FUTUREOFFPERSONALHEALTH

INQUIRIES: US.EDITORIAL@MEDIAPLANET.COM AND US.ADVERTISE@MEDIAPLANET.COM

PLEASE RECYCLE

Publisher Samantha Jahoda, Joanna Tronina, & David Wagner Business Developer Katie Konfino and Joelle Hernandez Managing Director Jordan Hernandez Lead Designer Kayla Mendez Designer Keziah Makoundou Lead Editor Jon Adams Copy Editor Taylor Rice Director of Content and Production Jordan Hernandez Cover Photo Don Flood All photos are credited to Getty Images unless otherwise specified. This section was created by Mediaplanet and did not involve USA Today.

2 READ MORE AT FUTUREOFFPERSONALHEALTH.COM

MEDIAPLANET

Fun with BB Cartoons
© 2022, BB Cartoons



The Village Bathman

VOY Funnies

Below is a fun word-play question for our readers:

Question: If Muhamad Ali was still alive, what would be his reason for refusing to wear a mask for COVID-19 pandemic?

Please send your answers privately to editor@voiceofyoruba.org

Selected responses will be printed in the next issue of VOY newsletter. Please include your name and email address in your submission. Multiple submissions are allowed.

Yoruba Translation Quizzes:

“Ara nta mi.” Literary translation submitted by Dr. ‘Bisi Adegbile: “I have a burning sensation in my body.”

Actual meaning: I am full of repulsive anger.

Here is a new one:

“Ata sa pami lori.”

Please include your name and email address in your submission. Multiple submissions are allowed.

Quarterly Recent and Forthcoming Birthdays

Looking back and forward in birthdays

January:

Lisa Aderonke Adegbile, January 3
Hammed Agboola, January 12
Samuel Banjoko, January 22,

February:

Dayo Odunsi, February 23

March:

Remi Oyebanjo, March 7
Nkechi Agboola, March 23



April:

Alice Okunade, April 6

May:

Christiana Okunade, May 5
Gabriel Okunade, May 10
Bisi Adegbile, May 18
Joan Apapa, May 29

June:


Gloria Iselaiye, June 13
Samuel Okunade, June 22
Yomi Omilakin, June 29



It is a “**Cakelicious**” Birthday Celebration!



Now available from the University of Lagos Press




This is one case we can judge a book by its cover, and rightfully so. The image on the front cover of this book was chosen by design to be a ready reference for Nigeria's geographical landscape. Readers have commented that they often refer to the cover as a sort of an encyclopedia of where the various states of Nigeria are situated. Even without opening the pages to read the book, readers are benefiting from the educational reference offered by the front cover. Happy viewing the cover (and hopefully, reading too).

This is Highly Recommended!

“*Dignity of Womanhood*” by Lilian Chudey from Namibia

Following the theme of March being Women’s History Month, VOY recommends “**Dignity of Womanhood**” published by Lilian Chudey Pride, who happens to be a professional mentee of VOY’s editor.

This book will help you as a woman to discover your role, which is far beyond that of just beauty. Learn how differences in roles and body constitution do not mean differences in essential values. The book is available on www.amazon.com as well as through info@beyondthevalepublishing.com.



The author also hosts the website, www.iWriteAfrica.com, a website created to promote Africa, her rich soil, her beauty and strength through inspired articles and photographs. Readers are encouraged to take a look and exude the pride of Africa.

Community Advertisements for Food, Fun, Friendship, Fellowship, and Fashion

Universal Export & Logistics LLC

We can get your stuff from here to there!
USA to Nigeria, No Problem.

UniveralExport&Logistics LLC

P: (267) 815-6730

E: Universalexportllc2020@gmail.com


- *Containerize Shipment
- *Ro/Ro Shipment
- *Moving within the US&Canada
- *Storage/warehouse in Lagos
- *Bureau de change



Oluwole Ibrahim Abduljelil
Tested & Trusted
Still soliciting for your referrals



Below is a helpful tool for managing your time rapidly and efficiently.







No temptation here. Just making a point



Èja Èpẹ ti ẹ nbere fun ni yi o. Odun bi oyin o.




AFRICAN RESTAURANT & GRILL, Serving and Thriving!

Pop in and give it a bite.

Serving all your favorites:

- Fish pepper soup
- Goat meat pepper soup
- Vegetable soup
- Yam porridge
- Fried tilapia
- Suya
- Meat pie
- Jollof rice
- Fried rice
- Rice & Stew meal
- Rice & Beans meal
- Assorted meat stew



Serving all your favorites:

- Whole tilapia
- Grilled lamb
- Pepper chicken
- Pepper goat meat
- Chin-chin
- Akara
- Moin-moin
- Puff-puff
- Fried plantain
- Fufu & Stew
- Egusi soup
- Okra soup



Eat authentic Nigerian cuisine to get fully nourished.

Spring is the season of trees blooming and needing grooming. Do you know whom to call?

F&F Tree Service.

F&F
TREE SERVICE

Email: info@FandFTrees.com
Web: FandFTrees.com


BONDED & INSURED
F&F
TREE SERVICE

[8733]
937-520-TREE
937-426-TREE

Daniel Iselaiye
President

BBB "...with God all things are possible"

When your teeth shatter, whom you gonna call?

 **Dr. Bamidele J Apapa D.D.S**
MAXILLOFACIAL SURGERY IMPLANT SURGERY DENTO-ALVEOLAR SURGERY

www.drapapa.com
937-298-5239

WELCOME TO DR. BAMIDELE J APAPA DDS INC

ORAL & MAXILLOFACIAL SURGERY AT ITS BEST

COME AND EXPERIENCE OUR SERVICES TODAY

ASK YOUR DENTIST TO REFER YOU TO US

Welcome to Dr. Bamidele J. Apapa DDS INC.

We specialize in Oral and Maxillofacial Surgery. Our office provides a unique relaxing atmosphere, while our staff is committed to giving each patient a positive surgical experience.

From the moment you walk into our serene waiting area, to the moment you leave our spacious surgical rooms, we go above and beyond making your visit as comfortable as possible.

Dr Apapa

Doctor Apapa has achievements and awards in the field of Oral maxillofacial surgery. Get to know the doctor!

**When your clothes become tatter at their age-worn stage, whom you gonna call?
Yeah, you got it!**



LAMIDI THE TAILOR, LLC

PHONE: (937) 825-8992

EMAIL: HAMEDAGBOOLA@YAHOO.COM



SERVICES

1) NATIVE ATTIRE:

Buba & Iro; Bubu for Women; Sokoto, Buba, Agbada, Dansiki & Caps for Adults & Children. Simple Embroidery on finished products.

2) Shortening, alterations & amendments are accepted, if feasible.

3) Will pick up materials where possible in Ohio.

4) Out of States may ship materials by UPS, along with old fitting examples to tailor after. Completed work will be shipped back promptly.



OUR PLEDGE

A Trial Will Convince You!

When your stomach starts growling for home food, Call Afro Meals.

"EXPERIENCE THE CULTURE"

AFROMEALS

INTRODUCING THE COMMUNITY TO AFRICAN & CARIBBEAN FOODS

SERVICES

- CATERING
- PRIVATE EVENT
- COOKING CLASS
- PICK-UP & DELIVERY

CONTACT US

240-486-1979
AFROMEALS.COM
AFROMEALS@GMAIL.COM

When you run out of original ingredients, where you gonna go?
(No fake substitutes o)

Tropical Super Market

3200 N. Main Street, Dayton, OH 45405


Telephone: 937-277-4430


New
Location




For all your African Ethnic Cooking Needs



When your fashion needs upgrading, whom you gonna call?


... same home favourites stuff



 chemtag fashion
 chemtag fashion
 chemtagfashion@gmail.com

@ #5250 N. Dixie Dr, Unit C, Dayton Ohio 45414
937-430-1911

OPEN: Monday - Friday 10.00am-7.00pm; Saturday 10.00am-6.00pm
Closed on sundays

That's all for now, folks!!!

Happy New Second Quarter of the Year! See you next quarter.

2021/2023 Officers of Egbe Omo Yoruba

President:	Dr. (Mrs.) Funmi Adegbile
Vice-President:	Professor Abayomi Ajayi-Majebi
Secretary:	Mrs. Ronke Odunsi
Asst. Secretary:	Professor Hammed Agboola
Treasurer:	Dr. Dayo Odunsi
Social Secretary:	Mrs. Gloria Iselaiye
Newsletter Editor:	Professor Deji Badiru
Parliamentarian:	Dr. Bisi Adegbile
Webmaster:	Mrs. Iswat Badiru

Donate to Advance Egbe

Egbe can now receive online donations directly through the website. Please go to www.VoiceOfYoruba.org and Click on **Donation**. Donations can be made via Paypal or Credit Card.

From the Editor



To VOY readers, *Thank you..*

